Madrigal Pharma (MDGL) Tops Q4 EPS by $1.77, Beats on Revenue

Madrigal Pharma (NASDAQ: MDGL) reported Q4 EPS of ($2.71), $1.77 better than the analyst estimate of ($4.48). Revenue for the quarter came in at $103.32 million versus the consensus estimate of $87.7 million.

For earnings history and earnings-related data on Madrigal Pharma (MDGL) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• MakeMyTrip (MMYT) PT Raised to $84 at Goldman Sachs
• SEGG Media sues short seller for $20M over stock report